Clinical Trial Update: DE-111 Against Timolol Ophthalmic Solution 0.5% [Phase 3]

View source ↗

Summary

Phase 3 trial comparing DE-111 against Timolol ophthalmic solution 0.5% for open-angle glaucoma and ocular hypertension; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• DE-111
• Timolol ophthalmic solution 0.5% (Timolol)

Snippet

Sponsor: Santen Pharmaceutical Co., Ltd. | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-05-15